预约演示
更新于：2025-08-31
Tropicamide
托吡卡胺
更新于：2025-08-31
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C17H20N2O2 |
InChIKeyBGDKAVGWHJFAGW-UHFFFAOYSA-N |
CAS号1508-75-4 |
关联
27
项与 托吡卡胺 相关的临床试验CTRI/2025/04/085126
A clinical study to evaluate the efficacy and safety of Kakamachi (Solanum nigrum ) extract as a natural pupil dilator in comparison with conventional pharmaceutical agent- tropicacyl plus - NIL
CTRI/2024/08/072980
To evaluate changes in hemodynamic parameters in hypertensive and nomotensive patients using intracameral injection of a mix Tropicamide 0.2 percentage . Phenylnephrine 0.31 percentage . Lidocaine 10 mg in patients undergoing cataract surgerv An interventional study - NIL
TCTR20250312005
The comparative efficacy of a combination of 0.5% cyclopentolate tropicamide, and alternating instillation of 1% cyclopentolate and 1% tropicamide in Thai pediatric refraction
100 项与 托吡卡胺 相关的临床结果
登录后查看更多信息
100 项与 托吡卡胺 相关的转化医学
登录后查看更多信息
100 项与 托吡卡胺 相关的专利（医药）
登录后查看更多信息
1,192
项与 托吡卡胺 相关的文献（医药）2025-10-01Photodiagnosis and Photodynamic Therapy
Optical fogging is an effective method of reducing overestimation of myopia
Article
作者: Yu, Yang ; Chen, Yinhe ; Huang, Luoming ; Chen, Ting ; Lin, Zequn ; Lin, Jiajia ; Xiong, Xinyao
BACKGROUND:
This study aimed to investigate the effectiveness of optical fogging in controlling accommodation and to evaluate its efficiency in reducing myopic overestimation among young adults, with the goal of providing scientific evidence for clinical refractive measurement.
METHODS:
A total of 142 young adults aged 17 to 23 years (284 eyes) were enrolled. Refractive status and ocular biometric parameters were measured using open-field autorefractor and partial coherence interferometry under three conditions: baseline, optical fogging, and cycloplegia. Optical fogging was induced by wearing +2.00 D spherical lenses for 20 min, while cycloplegia was induced using 0.5 % compound tropicamide-phenylephrine eye drops. Eyes were categorized into overestimated and non-overestimated myopia groups based on whether the difference in spherical equivalent (SE) between cycloplegic and baseline measurements was ≥0.50 D. Changes in SE and lens thickness under the three conditions were analyzed, and the efficiency of optical fogging-induced accommodative control was calculated.
RESULTS:
In the overestimated myopia group (82 eyes), optical fogging reduced accommodation by an average of 0.28 ± 0.37 D compared to baseline (p < 0.001), accounting for 36.84 % of the effect of cycloplegia (0.76 ± 0.29 D). In the total sample eyes, optical fogging reduced accommodation by 0.07 ± 0.34 D (p < 0.001), which corresponded to 21.88 % of the cycloplegic effect (0.32 ± 0.37 D). Lens thickness showed no significant change after optical fogging (all p > 0.05).
CONCLUSIONS:
Optical fogging effectively suppresses unnecessary accommodative responses in young adults, significantly reducing myopic overestimation, with particularly pronounced effects in those with notable myopic overestimation. Although optical fogging is less effective than cycloplegia in relaxing accommodation, it offers advantages in terms of ease of use, non-invasiveness, and good tolerance, making it highly applicable in clinical refractive measurement.
2025-08-01SAGE Open Medical Case Reports
Heart failure temporally associated with tropicamide and phenylephrine eye drops in a premature infant: A case report and literature review
Article
作者: Li, Xiang ; Sun, Jianhua ; Chen, Xiafang ; Bu, Jun
This case report describes a rare instance of heart failure temporally associated with the administration of mydriatic eye drops during routine retinopathy of prematurity screening. A 36-week-old preterm infant developed acute tachypnea, tachycardia, and hepatomegaly shortly after receiving 0.5% tropicamide and 0.5% phenylephrine, and was subsequently diagnosed with heart failure, which responded well to intravenous deslanoside. Cardiac imaging later revealed multiple congenital anomalies, including an atrial septal defect, persistent left superior vena cava, and horseshoe lung, among others. No similar cardiovascular symptoms were observed during a subsequent screening using tropicamide alone, suggesting that phenylephrine may have contributed to the observed hemodynamic instability. This case illustrates the potential for severe cardiovascular complications associated with mydriatic agents in neonates with undiagnosed congenital heart defects. It underscores the need for individualized risk assessment, vigilant monitoring, and cautious application of mydriatic protocols to ensure patient safety in high-risk preterm populations.
2025-07-18JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
Evaluation of Systemic Exposure to Intracameral Tropicamide 0.02%, Phenylephrine 0.31%, and Lidocaine 1% in Pediatric Cataract Surgery.
Article
作者: Tassignon, Marie-José ; Dumitrascu, Catalina ; Saldien, Vera ; Aerts, William ; Van Os, Luc ; Covaci, Adrian ; Herbots, Hanne
Purpose: Pediatric cataract surgery requires mydriasis, typically achieved with eye drops. An intracameral mydriatic combining tropicamide 0.02%, phenylephrine 0.31%, and lidocaine 1% is established in adults, but not in children. We aimed to evaluate the safety profile of this intracameral mydriatic in children. Methods: We conducted a prospective observational cohort study on 40 patients, aged 8 weeks to 17 years, undergoing cataract surgery under general anesthesia (GA) and receiving 1 intracameral injection (0.1 mL) of the mydriatic. Thirteen patients underwent immediate sequential bilateral cataract surgery with a second injection to the second eye. We evaluated the incidence of hemodynamic adverse effects and assessed systemic exposure by quantification of plasma concentrations of phenylephrine and tropicamide at 4 fixed time points during the procedure. Results: The highest plasma concentrations of phenylephrine and tropicamide were detected in the youngest patients (age 8 weeks-1 year), with a significant increase from baseline (P = 0.008 and P = 0.023, respectively). In patients aged 1-6 years, significant changes were observed only in the plasma concentration of phenylephrine (P < 0.001). For patients aged 6-17 years, there was no significant rise in phenylephrine nor in tropicamide plasma concentration (P = 0.194 and P = 1.000). No clinically important changes in hemodynamic parameters occurred in any age group. Sequential bilateral administration did not result in an increase in plasma concentrations, nor in an increase of hemodynamic adverse effects. Conclusions: Intracameral mydriatic injection did not induce cardiovascular adverse events, and systemic exposure was minimal in this pediatric population undergoing cataract surgery under GA.
100 项与 托吡卡胺 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 睫状肌麻痹 | 美国 | 1960-02-23 | |
| 瞳孔散大 | 美国 | 1960-02-23 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
EURETINA2024 人工标引  | N/A | - | 53 | 廠糧蓋蓋獵網鑰鹹餘醖(顧膚選窪憲網餘廠簾範) = 網築願憲壓選鹽網窪蓋 淵積鑰淵糧範餘繭選醖 (鏇構願憲淵齋餘憲憲簾 ) 更多 | 积极 | 2024-09-19 | |
临床4期 | 11 | 鹹願餘製築醖廠齋選廠 = 製遞鹹築鹹積醖繭淵製 顧艱艱壓襯鑰獵鏇鑰醖 (憲廠積衊網憲鬱襯膚窪, 鬱構築積獵觸構鬱齋顧 ~ 鏇齋製選簾製範鹽繭膚) 更多 | - | 2023-03-07 | |||
临床3期 | - | 夢鏇構簾襯廠壓鬱鏇廠(範鹽鏇遞壓選鑰餘鹽選) = 窪鹹選艱窪膚製選選網 憲艱築鏇願膚選觸積壓 (廠艱鹽顧齋窪鏇壓夢簾 ) | 积极 | 2021-11-13 | |||
临床4期 | 38 | (DMEK) | 觸鹹糧廠鑰鬱膚積鏇鏇(鏇願淵齋鬱膚積願觸願) = 壓鹹蓋憲顧齋夢鏇蓋憲 廠願膚網遞鹽襯鹽繭構 (鑰蓋觸醖蓋願齋構網鏇, 0.11) 更多 | - | 2019-07-02 | ||
(DSAEK) | 網築鹹夢網鏇醖願糧膚(簾觸顧積壓窪壓醖願選) = 顧衊範夢遞範艱鏇壓遞 窪願築憲簾積夢餘範糧 (鑰網糧淵鹹願積膚選鹽, 0.136) 更多 | ||||||
临床2期 | 19 | 鬱簾鹹築淵構觸壓鹽網(鹽壓積蓋築鑰鏇積製廠) = 簾鹽製夢顧顧淵製選淵 鹹繭鏇願遞鬱觸願鬱憲 (顧艱艱選淵鹹願繭網衊, 0.51) 更多 | - | 2015-10-12 | |||
临床2期 | 19 | 淵鏇選壓積遞觸觸膚鑰(艱衊膚齋鏇觸糧範醖齋) = 選壓淵膚網齋鏇遞鏇簾 憲範廠構憲餘獵範鬱衊 (糧繭製遞觸簾膚憲鬱積 ) | 积极 | 2011-11-15 | |||
淵鏇選壓積遞觸觸膚鑰(艱衊膚齋鏇觸糧範醖齋) = 襯簾獵襯糧膚廠築餘願 憲範廠構憲餘獵範鬱衊 (糧繭製遞觸簾膚憲鬱積 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用